Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 6 (June)

1. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.
   J Mass Spectrom, 43(6): 736-52. [Abstract] [Full-text]
2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
   Invest Ophthalmol Vis Sci, 49(6): 2348-56. [Abstract] [Full-text]
3. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma.
   Invest Ophthalmol Vis Sci, 49(6): 2337-42. [Abstract] [Full-text]
4. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations.
   Ann Oncol. [Abstract] [Full-text]
5. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
   Leuk Res. [Abstract] [Full-text]
6. Use of Imatinib Mesylate in Gastrointestinal Stromal Tumours: Pan-Birmingham Cancer Network Experience.
   Clin Oncol (R Coll Radiol). [Abstract] [Full-text]
7. Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol.
   FASEB J, 22(6): 1894-904. [Abstract] [Full-text]
8. Induced Disorder in Protein-Ligand Complexes as a Drug-Design Strategy.
   Mol Pharm, 5(3): 430-437. [Abstract] [Full-text]
9. Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
   Oncogene. [Abstract] [Full-text]
10. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
    Ann Surg, 247(6): 1011-8. [Abstract] [Full-text]
11. Current status of therapy for chronic myeloid leukemia: a review of drug development.
    Future Oncol, 4(3): 359-77. [Abstract] [Full-text]
12. The current status and evolving role of sunitinib in non-small cell lung cancer.
    J Thorac Oncol, 3(6): S119-23. [Abstract] [Full-text]
13. A malignant omental extra-gastrointestinal stromal tumor on a young man: a case report and review of the literature.
    World J Surg Oncol, 6: 50. [Abstract] [Full-text]
14. A multidisciplinary approach for the treatment of GIST liver metastasis.
    World J Surg Oncol, 6: 46. [Abstract] [Full-text]
15. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
    Curr Opin Oncol, 20(4): 433-7. [Abstract] [Full-text]
16. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Blood. [Abstract] [Full-text]
17. The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.
    Curr Opin Oncol, 20(4): 428-32. [Abstract] [Full-text]
18. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Anticancer Drugs, 19(6): 607-12. [Abstract] [Full-text]
19. Imatinib mesylate for the treatment of chronic myeloid leukemia.
    Expert Rev Anticancer Ther, 8(6): 853-64. [Abstract] [Full-text]
20. Pneumonia caused by Candida krusei and Candida glabrata in a patient with chronic myeloid leukemia receiving imatinib mesylate treatment.
    Med Mycol, 46(3): 259-63. [Abstract] [Full-text]
21. Mathematical models of cancer stem cells.
    J Clin Oncol, 26(17): 2854-61. [Abstract] [Full-text]
22. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Cancer. [Abstract] [Full-text]
23. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
    Br J Haematol. [Abstract] [Full-text]
24. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
    Leukemia, 22(6): 1184-90. [Abstract] [Full-text]
25. The effects of imatinib on pregnancy outcome.
    Blood, 111(12): 5505-8. [Abstract] [Full-text]
26. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
    Leukemia, 22(6): 1117-24. [Abstract] [Full-text]
27. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Leukemia, 22(6): 1200-6. [Abstract] [Full-text]
28. RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
    Leukemia, 22(6): 1131-8. [Abstract] [Full-text]
29. Surgical Outcomes of Patients with Gastrointestinal Stromal Tumors in the Era of Targeted Drug Therapy.
    J Gastrointest Surg. [Abstract] [Full-text]
30. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
    J Cutan Pathol. [Abstract] [Full-text]
31. Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer.
    Mol Cell Proteomics. [Abstract] [Full-text]
32. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
    Leukemia, 22(6): 1191-9. [Abstract] [Full-text]
33. O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma.
    Invest New Drugs. [Abstract] [Full-text]
34. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
    Expert Opin Investig Drugs, 17(7): 1127-36. [Abstract] [Full-text]
35. Therapeutic options for patients with clonal and idiopathic hypereosinophia.
    Expert Opin Investig Drugs, 17(7): 1039-50. [Abstract] [Full-text]
36. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis.
    Cardiovasc Res, 79(1): 118-26. [Abstract] [Full-text]
37. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
    Int J Clin Oncol, 13(3): 244-51. [Abstract] [Full-text]
38. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges.
    Expert Opin Ther Targets, 12(7): 883-903. [Abstract] [Full-text]
39. Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.
    Int J Hematol. [Abstract] [Full-text]
40. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
    Clin Cancer Res, 14(12): 3906-15. [Abstract] [Full-text]
41. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Clin Cancer Res, 14(12): 3881-8. [Abstract] [Full-text]
42. Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases.
    Bioconjug Chem, 19(6): 1164-9. [Abstract] [Full-text]
43. Bcr-Abl induces autocrine IGF-1 signaling.
    Oncogene, 27(27): 3831-44. [Abstract] [Full-text]
44. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Oncology, 73(5): 324-7. [Abstract] [Full-text]
45. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Proc Natl Acad Sci U S A, 105(24): 8387-92. [Abstract] [Full-text]
46. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
    Am J Respir Crit Care Med, 178(1): 81-8. [Abstract] [Full-text]
47. Metabolism and disposition of dasatinib after oral administration to humans.
    Drug Metab Dispos, 36(7): 1357-64. [Abstract] [Full-text]
48. Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
    PLoS Comput Biol, 4(6): e1000095. [Abstract] [Full-text]
49. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
    J Biol Chem, 283(26): 18292-302. [Abstract] [Full-text]
50. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    J Surg Oncol, 98(1): 27-33. [Abstract] [Full-text]
51. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis.
    J Am Acad Dermatol. [Abstract] [Full-text]
52. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Leuk Res. [Abstract] [Full-text]
53. Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
    Leuk Lymphoma, 49(6): 1168-77. [Abstract] [Full-text]
54. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.
    Blood. [Abstract] [Full-text]
55. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
    Proteomics, 8(12): 2394-406. [Abstract] [Full-text]
56. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
    Blood, 112(1): 53-5. [Abstract] [Full-text]
57. Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.
    Ann Oncol, 19(7): 1320-6. [Abstract] [Full-text]
58. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Clin Nucl Med, 33(7): 486-7. [Abstract] [Full-text]
59. A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
    J Clin Pathol, 61(7): 863-5. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.